JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) ...

Core Insights - Redwire Corporation (RDW) shares increased by 7.6% to close at $16.53, supported by high trading volume, and have gained 18.2% over the past four weeks [1][2] Company Performance - Redwire highlighted a strong 30% growth and profitability during its presentation at the Jefferies Space Summit, emphasizing its expansion into the defense market through strategic acquisitions like Edge Autonomy [2] - The company is expected to report a quarterly loss of $0.11 per share, reflecting a year-over-year change of +59.3%, with revenues projected at $106.8 million, up 36.7% from the previous year [3] Earnings Estimates - The consensus EPS estimate for Redwire has been revised down by 88.2% over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] - Despite the positive revenue growth expectations, the negative trend in earnings estimates suggests caution regarding future stock performance [4] Industry Context - Redwire Corporation is part of the Zacks Aerospace - Defense industry, where Northrop Grumman (NOC) recently closed 3.1% lower at $484, with a 6% return over the past month [5] - Northrop Grumman's consensus EPS estimate remains unchanged at $6.73, representing a year-over-year change of +5.8%, and currently holds a Zacks Rank of 4 (Sell) [6]

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Cent ...

ICG Enterprise Trust plc NAV per Share of 2,011p; LTM NAV per Share Total Return of 6.3% (5 year annualised: 14.8%) Q1 Portfolio Return on a Local Currency Basis of 0.6%, offset by FX, resulting in Portfolio Return on a Sterling Basis of (2.4)% and NAV per Share Total Return of (2.6)% Total Proceeds of £149m, including £62m net proceeds from the sale of a portion of our Portfolio at a 5.5% discount and £48m from sale of Minimax (previously our largest portfolio company holding); Total New Investments of £48 ...

Highlights the Support of Oportun Founder and Former CEO James Gutierrez, who Wrote that Findell Has "Offered a Smart, Focused Plan to Restore Value"Outlines How the Company Forced a Costly Proxy Contest by Refusing to Fill Board Leadership Positions with Independent Directors Who Possess Lending Industry Experience and by Ousting Former OneMain Financial CFO Scott Parker from the BoardMakes Clear That Removing Failed CEO Raul Vazquez from the Board Would Strengthen the Board's Oversight of ManagementReiter ...

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and ...

Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel’s long-term safety profile remains favorableResults presented at PPMD’s 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results ...

Company Overview - FatPipe, Inc. is a pioneer in enterprise-class, application-aware, secure software-defined wide area network (SD-WAN) solutions, providing high levels of reliability, security, and optimization for Wide Area Networks (WANs) [1] - The company holds 12 U.S. patents related to multipath, software-defined networking, and its products are sold by over 200 resellers worldwide [3] Event Announcement - Dr. Ragula Bhaskar, Chairman and CEO of FatPipe, will present at the virtual Northland Capital Markets Growth Conference on June 25, 2025 [2] - Interested participants are encouraged to contact their Northland Capital Markets sales representative for additional details and meeting opportunities [2]

MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft, today announced that it will host a webcast investor presentation on Wednesday, June 25, 2025, at 2:00 PM ET. During the webcast, Nicholas Sosiak, CFO, will conduct a presentation that will cover key are ...

Outlines proactive steps taken by Board and management to drive long-term stockholder value Urges stockholders to vote “FOR” Oportun’s two nominees – CEO Raul Vazquez and Carlos Minetti – on the GREEN proxy card SAN CARLOS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven financial services company, today released an investor presentation in connection with the Company’s upcoming Annual Meeting of Stockholders, scheduled to be held on July 18, 2025. The presentation and add ...